Description
Rigosertib is a potent, specific PLK1 (Polo -Like Kinase 1) inhibitor (IC₅₀ = 9 nM). Rigosertib strongly inhibits the proliferation of cancer cell lines, with observed IC₅₀ values in the nanomolar range for both HeLa (115 nM) and C33A (45 nM) cells. In contrast, Rigosertib has a minimal effect on normal cell lines, BJ and Ect1/E6E7 (IC₅₀ > 0.1 mM).
Rigosertib is a potent, specific PLK1 (Polo -Like Kinase 1) inhibitor (IC₅₀ = 9 nM). Rigosertib strongly inhibits the proliferation of cancer cell lines, with observed IC₅₀ values in the nanomolar range for both HeLa (115 nM) and C33A (45 nM) cells. In contrast, Rigosertib has a minimal effect on normal cell lines, BJ and Ect1/E6E7 (IC₅₀ > 0.1 mM).
Alternate Name/Synonyms: Sodium (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate; ON-01910
Appearance: White solid
Formulation: N/A
CAS Number: 1225497-78-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₁H₂₄NNaO₈S
Molecular Weight: 473.47
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>5 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent, specific PLK1 (Polo -Like Kinase 1) inhibitor
MDL Number: N/A
PubChem CID: 23696523
SMILES: COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)[O-].[Na+]
InChi: InChI=1S/C21H25NO8S.Na/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24;/h5-11,22H,12-13H2,1-4H3,(H,23,24);/q;+1/p-1/b8-7+;
InChi Key: VLQLUZFVFXYXQE-USRGLUTNSA-M
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |